RU2018145184A - Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования - Google Patents
Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования Download PDFInfo
- Publication number
- RU2018145184A RU2018145184A RU2018145184A RU2018145184A RU2018145184A RU 2018145184 A RU2018145184 A RU 2018145184A RU 2018145184 A RU2018145184 A RU 2018145184A RU 2018145184 A RU2018145184 A RU 2018145184A RU 2018145184 A RU2018145184 A RU 2018145184A
- Authority
- RU
- Russia
- Prior art keywords
- paragraphs
- inhibitor
- chemotherapy
- subject
- malignant neoplasm
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 11
- 201000011510 cancer Diseases 0.000 title claims 11
- 238000011282 treatment Methods 0.000 title claims 5
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 title 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims 41
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 12
- 238000002512 chemotherapy Methods 0.000 claims 9
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 8
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 8
- 229910052697 platinum Inorganic materials 0.000 claims 7
- 208000017604 Hodgkin disease Diseases 0.000 claims 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 102000048776 human CD274 Human genes 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 102000048119 human PDCD1LG2 Human genes 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000002650 immunosuppressive therapy Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341921P | 2016-05-26 | 2016-05-26 | |
| US62/341,921 | 2016-05-26 | ||
| US201662423358P | 2016-11-17 | 2016-11-17 | |
| US62/423,358 | 2016-11-17 | ||
| US201762471459P | 2017-03-15 | 2017-03-15 | |
| US62/471,459 | 2017-03-15 | ||
| PCT/EP2017/062213 WO2017202744A1 (en) | 2016-05-26 | 2017-05-22 | Pd-1 / pd-l1 inhibitors for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018145184A true RU2018145184A (ru) | 2020-06-26 |
Family
ID=58745241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018145184A RU2018145184A (ru) | 2016-05-26 | 2017-05-22 | Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190144545A1 (OSRAM) |
| EP (1) | EP3464356A1 (OSRAM) |
| JP (1) | JP2019516748A (OSRAM) |
| KR (1) | KR20190012201A (OSRAM) |
| CN (1) | CN109195989A (OSRAM) |
| AU (1) | AU2017269675A1 (OSRAM) |
| BR (1) | BR112018073920A2 (OSRAM) |
| CA (1) | CA3025391A1 (OSRAM) |
| IL (1) | IL263178A (OSRAM) |
| MX (1) | MX2018014435A (OSRAM) |
| RU (1) | RU2018145184A (OSRAM) |
| SG (1) | SG11201810423XA (OSRAM) |
| TW (1) | TW201800108A (OSRAM) |
| WO (1) | WO2017202744A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| BR112017018234A2 (pt) | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| KR102712880B1 (ko) | 2015-06-16 | 2024-10-02 | 메르크 파텐트 게엠베하 | Pd-l1 길항제 조합 치료 |
| JP7014706B2 (ja) | 2015-07-13 | 2022-02-01 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法 |
| MX2019003755A (es) * | 2016-10-06 | 2019-08-12 | Pfizer | Regimen de dosificacion de avelumab para el tratamiento de cancer. |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| KR20200016899A (ko) | 2017-06-01 | 2020-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| US20210355223A1 (en) * | 2018-11-05 | 2021-11-18 | Pfizer Inc. | Combinations for Treating Cancer |
| BR112021008582A8 (pt) * | 2018-11-05 | 2023-02-07 | Merck Sharp & Dohme | Regime de dosagem de anticorpo anti-tigit para tratamento de câncer |
| WO2020135415A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| MX2022000853A (es) * | 2019-07-22 | 2022-03-17 | Seagen Inc | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer. |
| CN120437288A (zh) * | 2019-12-24 | 2025-08-08 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗卵巢癌的药物组合 |
| CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司（Us） | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
| EP4146345A2 (en) | 2020-05-05 | 2023-03-15 | Teon Therapeutics, Inc. | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
| WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
| WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
| WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
| KR20230128690A (ko) * | 2022-02-28 | 2023-09-05 | 주식회사 시선테라퓨틱스 | 핵산 복합체를 포함하는 폐암 예방 또는 치료용 조성물 |
| EP4554943A1 (en) | 2022-07-14 | 2025-05-21 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| RS61033B1 (sr) * | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| DK3043816T3 (da) * | 2013-09-11 | 2019-10-14 | Medimmune Ltd | Anti-b7-h1-antistoffer til behandling af tumorer |
| AR101210A1 (es) * | 2014-07-15 | 2016-11-30 | Genentech Inc | Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek |
| BR112017018234A2 (pt) * | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| KR102712880B1 (ko) * | 2015-06-16 | 2024-10-02 | 메르크 파텐트 게엠베하 | Pd-l1 길항제 조합 치료 |
-
2017
- 2017-05-22 RU RU2018145184A patent/RU2018145184A/ru not_active Application Discontinuation
- 2017-05-22 SG SG11201810423XA patent/SG11201810423XA/en unknown
- 2017-05-22 EP EP17724821.8A patent/EP3464356A1/en not_active Withdrawn
- 2017-05-22 MX MX2018014435A patent/MX2018014435A/es unknown
- 2017-05-22 JP JP2018561278A patent/JP2019516748A/ja active Pending
- 2017-05-22 CA CA3025391A patent/CA3025391A1/en not_active Abandoned
- 2017-05-22 US US16/304,338 patent/US20190144545A1/en not_active Abandoned
- 2017-05-22 CN CN201780032522.1A patent/CN109195989A/zh active Pending
- 2017-05-22 KR KR1020187037522A patent/KR20190012201A/ko not_active Withdrawn
- 2017-05-22 BR BR112018073920-0A patent/BR112018073920A2/pt not_active Application Discontinuation
- 2017-05-22 AU AU2017269675A patent/AU2017269675A1/en not_active Abandoned
- 2017-05-22 WO PCT/EP2017/062213 patent/WO2017202744A1/en not_active Ceased
- 2017-05-25 TW TW106117304A patent/TW201800108A/zh unknown
-
2018
- 2018-11-21 IL IL263178A patent/IL263178A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018014435A (es) | 2019-04-15 |
| SG11201810423XA (en) | 2018-12-28 |
| JP2019516748A (ja) | 2019-06-20 |
| CA3025391A1 (en) | 2017-11-30 |
| US20190144545A1 (en) | 2019-05-16 |
| BR112018073920A2 (pt) | 2019-02-26 |
| TW201800108A (zh) | 2018-01-01 |
| AU2017269675A1 (en) | 2019-01-17 |
| IL263178A (en) | 2018-12-31 |
| CN109195989A (zh) | 2019-01-11 |
| KR20190012201A (ko) | 2019-02-08 |
| EP3464356A1 (en) | 2019-04-10 |
| WO2017202744A1 (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018145184A (ru) | Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования | |
| JP2019516748A5 (OSRAM) | ||
| Aglietta et al. | A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer | |
| Biondani et al. | Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient | |
| JP2019515888A5 (OSRAM) | ||
| MX357100B (es) | Tratamiento de neoplasias hematologicas con un anticuerpo anti-cxcr4. | |
| US20050112130A1 (en) | Enhanced B cell cytotoxicity of CDIM binding antibody | |
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| TW202313113A (zh) | 藉由投予pd-1抑制劑治療皮膚癌之方法 | |
| Kansara et al. | Immunotherapy in hematologic malignancies | |
| JP2018522887A5 (OSRAM) | ||
| JP2019503387A5 (OSRAM) | ||
| Hoelzer | Novel antibody-based therapies for acute lymphoblastic leukemia | |
| JP2017510579A5 (OSRAM) | ||
| EP3554515A1 (en) | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors | |
| JP2019508433A5 (OSRAM) | ||
| Schmitz et al. | The role of immune checkpoints after cellular therapy | |
| EP3976193A1 (en) | Dosing of bispecific t cell engager | |
| Guo et al. | Targeting BCMA to treat multiple myeloma: updates from the 2021 ASH annual meeting | |
| Ju et al. | Advancements in the treatment of pediatric acute leukemia and brain tumor-continuous efforts for 100% cure | |
| Maino et al. | Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells | |
| Paillassa et al. | Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer. | |
| US20220125880A1 (en) | Method for treating checkpoint inhibitors induced adverse events | |
| MX2024005406A (es) | Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38. | |
| CA3214753A1 (en) | Dosing of bispecific t cell engager |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200525 |